Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer

Hanna K. Sanoff, Richard M. Goldberg, Anastasia Ivanova, Seamus O'Reilly, Samer S. Kasbari, Richard D. Kim, Ray McDermott, Dominic T. Moore, William Zamboni, William Grogan, Allen Lee Cohn, Tanios Bekaii-Saab, Gregory Leonard, Theresa Ryan, Olugbenga O. Olowokure, Nishan H. Fernando, John McCaffrey, Bassel F. El-Rayes, Anne M. Horgan, Gary Bradley SherrillGeorge Hosni Yacoub, Bert H. O'Neil

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer. This international, double-blind, placebo-controlled, multicenter trial assessed the efficacy of regorafenib with folinic acid, fluorouracil, and irinotecan (FOLFIRI) as a second-line treatment for metastatic colorectal cancer. METHODS: Patients with metastatic colorectal cancer who progressed on first-line oxaliplatin and fluoropyrimidine enrolled at 45 sites in the United States and Ireland. Patients, stratified by prior bevacizumab use, were randomized 2:1 to regorafenib or placebo. The treatment consisted of FOLFIRI on days 1 and 2 and days 15 and 16 with 160 mg of regorafenib or placebo on days 4 to 10 and days 18 to 24 of every 28-day cycle. Crossover was not allowed. The primary endpoint was progression-free survival (PFS). Under the assumption of a 75% event rate, 180 patients were required for 135 events to achieve 90% power to detect a hazard ratio (HR) of 0.65 with a 1-sided α value of.1. RESULTS: One hundred eighty-one patients were randomized (120 to regorafenib-FOLFIRI and 61 to placebo-FOLFIRI) with a median age of 62 years. Among these, 117 (65%) received prior bevacizumab or aflibercept. PFS was longer with regorafenib-FOLFIRI than placebo-FOLFIRI (median, 6.1 vs 5.3 months; HR, 0.73; 95% confidence interval [CI], 0.53-1.01; log-rank P =.056). The median overall survival was not longer (HR, 1.01; 95% CI, 0.71-1.44). The response rate was higher with regorafenib-FOLFIRI (34%; 95% CI, 25%-44%) than placebo-FOLFIRI (21%; 95% CI, 11%-33%; P =.07). Grade 3/4 adverse events with a >5% absolute increase from regorafenib included diarrhea, neutropenia, febrile neutropenia, hypophosphatemia, and hypertension. CONCLUSIONS: The addition of regorafenib to FOLFIRI as second-line therapy for metastatic colorectal cancer only modestly prolonged PFS over FOLFIRI alone. Cancer 2018.

Original languageEnglish (US)
Pages (from-to)3118-3126
Number of pages9
JournalCancer
Volume124
Issue number15
DOIs
StatePublished - Aug 1 2018

Fingerprint

irinotecan
Leucovorin
Fluorouracil
Colorectal Neoplasms
Placebos
Confidence Intervals
Disease-Free Survival
Therapeutics
oxaliplatin
regorafenib
Hypophosphatemia
Febrile Neutropenia

Keywords

  • angiogenesis inhibitor
  • chemotherapy
  • colorectal cancer
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sanoff, H. K., Goldberg, R. M., Ivanova, A., O'Reilly, S., Kasbari, S. S., Kim, R. D., ... O'Neil, B. H. (2018). Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer, 124(15), 3118-3126. https://doi.org/10.1002/cncr.31552

Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. / Sanoff, Hanna K.; Goldberg, Richard M.; Ivanova, Anastasia; O'Reilly, Seamus; Kasbari, Samer S.; Kim, Richard D.; McDermott, Ray; Moore, Dominic T.; Zamboni, William; Grogan, William; Cohn, Allen Lee; Bekaii-Saab, Tanios; Leonard, Gregory; Ryan, Theresa; Olowokure, Olugbenga O.; Fernando, Nishan H.; McCaffrey, John; El-Rayes, Bassel F.; Horgan, Anne M.; Sherrill, Gary Bradley; Yacoub, George Hosni; O'Neil, Bert H.

In: Cancer, Vol. 124, No. 15, 01.08.2018, p. 3118-3126.

Research output: Contribution to journalArticle

Sanoff, HK, Goldberg, RM, Ivanova, A, O'Reilly, S, Kasbari, SS, Kim, RD, McDermott, R, Moore, DT, Zamboni, W, Grogan, W, Cohn, AL, Bekaii-Saab, T, Leonard, G, Ryan, T, Olowokure, OO, Fernando, NH, McCaffrey, J, El-Rayes, BF, Horgan, AM, Sherrill, GB, Yacoub, GH & O'Neil, BH 2018, 'Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer', Cancer, vol. 124, no. 15, pp. 3118-3126. https://doi.org/10.1002/cncr.31552
Sanoff, Hanna K. ; Goldberg, Richard M. ; Ivanova, Anastasia ; O'Reilly, Seamus ; Kasbari, Samer S. ; Kim, Richard D. ; McDermott, Ray ; Moore, Dominic T. ; Zamboni, William ; Grogan, William ; Cohn, Allen Lee ; Bekaii-Saab, Tanios ; Leonard, Gregory ; Ryan, Theresa ; Olowokure, Olugbenga O. ; Fernando, Nishan H. ; McCaffrey, John ; El-Rayes, Bassel F. ; Horgan, Anne M. ; Sherrill, Gary Bradley ; Yacoub, George Hosni ; O'Neil, Bert H. / Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. In: Cancer. 2018 ; Vol. 124, No. 15. pp. 3118-3126.
@article{b05ac3055a894da4add6dd77e82e0d3b,
title = "Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer",
abstract = "BACKGROUND: Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer. This international, double-blind, placebo-controlled, multicenter trial assessed the efficacy of regorafenib with folinic acid, fluorouracil, and irinotecan (FOLFIRI) as a second-line treatment for metastatic colorectal cancer. METHODS: Patients with metastatic colorectal cancer who progressed on first-line oxaliplatin and fluoropyrimidine enrolled at 45 sites in the United States and Ireland. Patients, stratified by prior bevacizumab use, were randomized 2:1 to regorafenib or placebo. The treatment consisted of FOLFIRI on days 1 and 2 and days 15 and 16 with 160 mg of regorafenib or placebo on days 4 to 10 and days 18 to 24 of every 28-day cycle. Crossover was not allowed. The primary endpoint was progression-free survival (PFS). Under the assumption of a 75{\%} event rate, 180 patients were required for 135 events to achieve 90{\%} power to detect a hazard ratio (HR) of 0.65 with a 1-sided α value of.1. RESULTS: One hundred eighty-one patients were randomized (120 to regorafenib-FOLFIRI and 61 to placebo-FOLFIRI) with a median age of 62 years. Among these, 117 (65{\%}) received prior bevacizumab or aflibercept. PFS was longer with regorafenib-FOLFIRI than placebo-FOLFIRI (median, 6.1 vs 5.3 months; HR, 0.73; 95{\%} confidence interval [CI], 0.53-1.01; log-rank P =.056). The median overall survival was not longer (HR, 1.01; 95{\%} CI, 0.71-1.44). The response rate was higher with regorafenib-FOLFIRI (34{\%}; 95{\%} CI, 25{\%}-44{\%}) than placebo-FOLFIRI (21{\%}; 95{\%} CI, 11{\%}-33{\%}; P =.07). Grade 3/4 adverse events with a >5{\%} absolute increase from regorafenib included diarrhea, neutropenia, febrile neutropenia, hypophosphatemia, and hypertension. CONCLUSIONS: The addition of regorafenib to FOLFIRI as second-line therapy for metastatic colorectal cancer only modestly prolonged PFS over FOLFIRI alone. Cancer 2018.",
keywords = "angiogenesis inhibitor, chemotherapy, colorectal cancer, tyrosine kinase inhibitor",
author = "Sanoff, {Hanna K.} and Goldberg, {Richard M.} and Anastasia Ivanova and Seamus O'Reilly and Kasbari, {Samer S.} and Kim, {Richard D.} and Ray McDermott and Moore, {Dominic T.} and William Zamboni and William Grogan and Cohn, {Allen Lee} and Tanios Bekaii-Saab and Gregory Leonard and Theresa Ryan and Olowokure, {Olugbenga O.} and Fernando, {Nishan H.} and John McCaffrey and El-Rayes, {Bassel F.} and Horgan, {Anne M.} and Sherrill, {Gary Bradley} and Yacoub, {George Hosni} and O'Neil, {Bert H.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1002/cncr.31552",
language = "English (US)",
volume = "124",
pages = "3118--3126",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "15",

}

TY - JOUR

T1 - Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer

AU - Sanoff, Hanna K.

AU - Goldberg, Richard M.

AU - Ivanova, Anastasia

AU - O'Reilly, Seamus

AU - Kasbari, Samer S.

AU - Kim, Richard D.

AU - McDermott, Ray

AU - Moore, Dominic T.

AU - Zamboni, William

AU - Grogan, William

AU - Cohn, Allen Lee

AU - Bekaii-Saab, Tanios

AU - Leonard, Gregory

AU - Ryan, Theresa

AU - Olowokure, Olugbenga O.

AU - Fernando, Nishan H.

AU - McCaffrey, John

AU - El-Rayes, Bassel F.

AU - Horgan, Anne M.

AU - Sherrill, Gary Bradley

AU - Yacoub, George Hosni

AU - O'Neil, Bert H.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - BACKGROUND: Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer. This international, double-blind, placebo-controlled, multicenter trial assessed the efficacy of regorafenib with folinic acid, fluorouracil, and irinotecan (FOLFIRI) as a second-line treatment for metastatic colorectal cancer. METHODS: Patients with metastatic colorectal cancer who progressed on first-line oxaliplatin and fluoropyrimidine enrolled at 45 sites in the United States and Ireland. Patients, stratified by prior bevacizumab use, were randomized 2:1 to regorafenib or placebo. The treatment consisted of FOLFIRI on days 1 and 2 and days 15 and 16 with 160 mg of regorafenib or placebo on days 4 to 10 and days 18 to 24 of every 28-day cycle. Crossover was not allowed. The primary endpoint was progression-free survival (PFS). Under the assumption of a 75% event rate, 180 patients were required for 135 events to achieve 90% power to detect a hazard ratio (HR) of 0.65 with a 1-sided α value of.1. RESULTS: One hundred eighty-one patients were randomized (120 to regorafenib-FOLFIRI and 61 to placebo-FOLFIRI) with a median age of 62 years. Among these, 117 (65%) received prior bevacizumab or aflibercept. PFS was longer with regorafenib-FOLFIRI than placebo-FOLFIRI (median, 6.1 vs 5.3 months; HR, 0.73; 95% confidence interval [CI], 0.53-1.01; log-rank P =.056). The median overall survival was not longer (HR, 1.01; 95% CI, 0.71-1.44). The response rate was higher with regorafenib-FOLFIRI (34%; 95% CI, 25%-44%) than placebo-FOLFIRI (21%; 95% CI, 11%-33%; P =.07). Grade 3/4 adverse events with a >5% absolute increase from regorafenib included diarrhea, neutropenia, febrile neutropenia, hypophosphatemia, and hypertension. CONCLUSIONS: The addition of regorafenib to FOLFIRI as second-line therapy for metastatic colorectal cancer only modestly prolonged PFS over FOLFIRI alone. Cancer 2018.

AB - BACKGROUND: Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer. This international, double-blind, placebo-controlled, multicenter trial assessed the efficacy of regorafenib with folinic acid, fluorouracil, and irinotecan (FOLFIRI) as a second-line treatment for metastatic colorectal cancer. METHODS: Patients with metastatic colorectal cancer who progressed on first-line oxaliplatin and fluoropyrimidine enrolled at 45 sites in the United States and Ireland. Patients, stratified by prior bevacizumab use, were randomized 2:1 to regorafenib or placebo. The treatment consisted of FOLFIRI on days 1 and 2 and days 15 and 16 with 160 mg of regorafenib or placebo on days 4 to 10 and days 18 to 24 of every 28-day cycle. Crossover was not allowed. The primary endpoint was progression-free survival (PFS). Under the assumption of a 75% event rate, 180 patients were required for 135 events to achieve 90% power to detect a hazard ratio (HR) of 0.65 with a 1-sided α value of.1. RESULTS: One hundred eighty-one patients were randomized (120 to regorafenib-FOLFIRI and 61 to placebo-FOLFIRI) with a median age of 62 years. Among these, 117 (65%) received prior bevacizumab or aflibercept. PFS was longer with regorafenib-FOLFIRI than placebo-FOLFIRI (median, 6.1 vs 5.3 months; HR, 0.73; 95% confidence interval [CI], 0.53-1.01; log-rank P =.056). The median overall survival was not longer (HR, 1.01; 95% CI, 0.71-1.44). The response rate was higher with regorafenib-FOLFIRI (34%; 95% CI, 25%-44%) than placebo-FOLFIRI (21%; 95% CI, 11%-33%; P =.07). Grade 3/4 adverse events with a >5% absolute increase from regorafenib included diarrhea, neutropenia, febrile neutropenia, hypophosphatemia, and hypertension. CONCLUSIONS: The addition of regorafenib to FOLFIRI as second-line therapy for metastatic colorectal cancer only modestly prolonged PFS over FOLFIRI alone. Cancer 2018.

KW - angiogenesis inhibitor

KW - chemotherapy

KW - colorectal cancer

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85050972636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050972636&partnerID=8YFLogxK

U2 - 10.1002/cncr.31552

DO - 10.1002/cncr.31552

M3 - Article

C2 - 29905927

AN - SCOPUS:85050972636

VL - 124

SP - 3118

EP - 3126

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 15

ER -